Proteasome Inhibitors in Cancer Therapy

Overview

The ubiquitin-proteosome pathway is an area that is increasingly becoming appreciated as one of the most promising targets of drug discovery efforts to emerge in the last decade and this volume provides, for the first time, a centralized summary of groundbreaking research from numerous research centers that have participated in the development of this novel class of pharmacologic agents. Part I reviews the chemistry and cell biology of the proteasome while part II reviews the rational for proteasome inhibition in...

See more details below
Paperback (Softcover reprint of hardcover 1st ed. 2004)
$249.00
BN.com price
Other sellers (Paperback)
  • All (6) from $183.41   
  • New (6) from $183.41   
Sending request ...

Overview

The ubiquitin-proteosome pathway is an area that is increasingly becoming appreciated as one of the most promising targets of drug discovery efforts to emerge in the last decade and this volume provides, for the first time, a centralized summary of groundbreaking research from numerous research centers that have participated in the development of this novel class of pharmacologic agents. Part I reviews the chemistry and cell biology of the proteasome while part II reviews the rational for proteasome inhibition in cancer. Part III reviews the clinical trial program of proteasome inhibitors in a variety of tumor types

Read More Show Less

Editorial Reviews

From the Publisher
"Authoritative and illuminating...." - Tumori
Read More Show Less

Product Details

  • ISBN-13: 9781617374524
  • Publisher: Springer-Verlag New York, LLC
  • Publication date: 11/19/2010
  • Series: Cancer Drug Discovery and Development Series
  • Edition description: Softcover reprint of hardcover 1st ed. 2004
  • Edition number: 1
  • Pages: 313
  • Product dimensions: 7.00 (w) x 10.00 (h) x 0.69 (d)

Table of Contents

I. Cancer Drug Development

Cancer Drug Development: Challenges in a Competitive Market
Barry Greene and Michael Kauffman

II. Chemistry and Cell Biology of the Proteasome

Introduction to the Proteasome and Its Inhibitors: Biochemistry and Cell Biology
Alfred L. Goldberg

Structures of the Yeast Proteasome Core Particle in Complex with Inhibitors
Michael Groll and Robert Huber

Natural Product and Synthetic Proteasome Inhibitors
Kyung Bo Kim and Craig M. Crews

Other Proteasome Inhibitors
Carlos García-Echeverría

The Proteasome in Cell-Cycle Regulation
Julian Adams

Proteasome Inhibition and Apoptosis
Simon A. Williams and David J. McConkey

The Proteasome and the COMPARE Algorithm
Susan L. Holbeck and Edward A. Sausville

III. Rationale for Proteasome Inhibitors in Cancer

The Proteasome in Cancer Biology and Therapy
Frank Pajonk and William H. McBride

Radiosensitization and Proteasome Inhibition
Carter Van Waes, John B. Sunwoo, William DeGraff, and James B. Mitchell

Proteasome-Dependent Regulation of NF-kB Activation: Molecular Targeting of Chemotherapy Resistance
James C. Cusack, Jr.

Bortezomib with Taxanes
Leonard Liebes, Bruce Ng, Yi-He Ling, and Roman Perez-Soler

Proteasome Inhibitor Therapy in a Brain Tumor Model
Jeffrey J. Olson, Geoffrey Bowers, and Zhaobin Zhang

Anthracyclines and Bortezomib
Robert Z. Orlowski

TNF-Related Apoptosis-Inducing Ligand (TRAIL): Combination with Proteasome Inhibition For Anticancer Therapy?
Thomas J. Sayers

Rationale for Combining the Proteasome Inhibitor Bortezomib with Cisplatin
Edward G. Mimnaugh and Leonard M. Neckers

The Effects of the HIV-1 Protease Inhibitor Ritonavir on Proteasome Activity and Antigen Presentation
Marcus Groettrup, Rita deGiuli, and Gunter Schmidtke

Function(s) of the Ubiquitin-Proteasome System in Retrovirus Budding
Ulrich Schubert

IV. Clinical Trials

Preclinical Development of Bortezomib (VELCADE™): Rationale for Clinical Studies
Julian Adams, Peter J. Elliott, and Page Bouchard

Phase I Trials: Bortezomib Alone and in Combination With Standard Chemotherapies
Dixie-Lee W. Esseltine and David P. Schenkein

Clinical Molecular Diagnostics for Proteasome Inhibitors in Cancer Therapy
Jeffrey S. Ross, Gerald P. Linette, Geoffrey S. Ginsburg, William Trepicchio, Oscar Kashala, Rebecca Mosher, Jeffrey Brown, George Mulligan, Jim Deeds, and James Stec

Phase II Trials of Bortezomib for the Treatment of Multiple Myeloma
Kenneth C. Anderson

Index

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)